Literature DB >> 33290846

Metabolic regulation of prostate cancer heterogeneity and plasticity.

Claudia Peitzsch1, Ielizaveta Gorodetska2, Daria Klusa3, Qihui Shi4, Tiago C Alves5, Klaus Pantel6, Anna Dubrovska7.   

Abstract

Metabolic reprogramming is one of the main hallmarks of cancer cells. It refers to the metabolic adaptations of tumor cells in response to nutrient deficiency, microenvironmental insults, and anti-cancer therapies. Metabolic transformation during tumor development plays a critical role in the continued tumor growth and progression and is driven by a complex interplay between the tumor mutational landscape, epigenetic modifications, and microenvironmental influences. Understanding the tumor metabolic vulnerabilities might open novel diagnostic and therapeutic approaches with the potential to improve the efficacy of current tumor treatments. Prostate cancer is a highly heterogeneous disease harboring different mutations and tumor cell phenotypes. While the increase of intra-tumor genetic and epigenetic heterogeneity is associated with tumor progression, less is known about metabolic regulation of prostate cancer cell heterogeneity and plasticity. This review summarizes the central metabolic adaptations in prostate tumors, state-of-the-art technologies for metabolic analysis, and the perspectives for metabolic targeting and diagnostic implications.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Circulating tumor cells; Disseminated tumor cells; Metabolic biomarkers; Metabolic heterogeneity; Metabolic reprogramming; Metabolic therapies; Metabolomics; Prostate cancer

Mesh:

Year:  2020        PMID: 33290846     DOI: 10.1016/j.semcancer.2020.12.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  9 in total

1.  Cancer cell heterogeneity and plasticity: From molecular understanding to therapeutic targeting.

Authors:  Dean G Tang; Toru Kondo
Journal:  Semin Cancer Biol       Date:  2021-10-06       Impact factor: 17.012

2.  Functional metabolome profiling may improve individual outcomes in colorectal cancer management implementing concepts of predictive, preventive, and personalized medical approach.

Authors:  Yu Yuan; Chenxin Yang; Yingzhi Wang; Mingming Sun; Chenghao Bi; Sitong Sun; Guijiang Sun; Jingpeng Hao; Lingling Li; Changliang Shan; Shuai Zhang; Yubo Li
Journal:  EPMA J       Date:  2022-01-27       Impact factor: 6.543

Review 3.  Amino Acid Transporters on the Guard of Cell Genome and Epigenome.

Authors:  Uğur Kahya; Ayşe Sedef Köseer; Anna Dubrovska
Journal:  Cancers (Basel)       Date:  2021-01-02       Impact factor: 6.639

4.  Identification of miRNA-Mediated Subpathways as Prostate Cancer Biomarkers Based on Topological Inference in a Machine Learning Process Using Integrated Gene and miRNA Expression Data.

Authors:  Ziyu Ning; Shuang Yu; Yanqiao Zhao; Xiaoming Sun; Haibin Wu; Xiaoyang Yu
Journal:  Front Genet       Date:  2021-03-24       Impact factor: 4.599

5.  Identification of Prognostic Metabolomic Biomarkers at the Interface of Mortality and Morbidity in Pre-Existing TB Cases Infected With SARS-CoV-2.

Authors:  Ilhame Diboun; Farhan S Cyprian; Najeha Rizwana Anwardeen; Hadi M Yassine; Mohamed A Elrayess; Samreen Mumtaz Rahmoon; Sarah Khaled Sayed; Sven Schuchardt; Malkan Khatib; Devendra Bansal; Elmoubashar Abu Baker Abd Farag; Mohamed M Emara; Abdallah M Abdallah
Journal:  Front Cell Infect Microbiol       Date:  2022-07-22       Impact factor: 6.073

6.  Comparative Analysis of Proteomes and Phosphoproteomes in Patients with Prostate Cancer Using Different Surgical Conditions.

Authors:  Hee-Sung Ahn; Jeonghun Yeom; Hwangkyo Jeong; Won Young Park; Ja Yoon Ku; Byeong Jin Kang; Kyung Hwan Kim; Chan Ho Lee; Sangheon Song; Sun Sik Bae; Kyunggon Kim; Hong Koo Ha
Journal:  World J Mens Health       Date:  2022-01-01       Impact factor: 6.494

7.  FABP6 Expression Correlates with Immune Infiltration and Immunogenicity in Colorectal Cancer Cells.

Authors:  Wenping Lian; Zhongquan Wang; Yajie Ma; Yalin Tong; Xinyu Zhang; Huifang Jin; Shuai Zhao; Ruijing Yu; Shaotan Ju; Xinyun Zhang; Xiaona Guo; Tao Huang; Xianfei Ding; Mengle Peng
Journal:  J Immunol Res       Date:  2022-08-17       Impact factor: 4.493

8.  Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in Prostate Cancer.

Authors:  Renli Ning; Yulei Pei; Ping Li; Wei Hu; Yong Deng; Zhengshan Hong; Yun Sun; Qing Zhang; Xiaomao Guo
Journal:  Front Public Health       Date:  2021-12-07

9.  GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.

Authors:  Anna Mukha; Uğur Kahya; Annett Linge; Oleg Chen; Steffen Löck; Vasyl Lukiyanchuk; Susan Richter; Tiago C Alves; Mirko Peitzsch; Vladyslav Telychko; Sergej Skvortsov; Giulia Negro; Bertram Aschenbrenner; Ira-Ida Skvortsova; Peter Mirtschink; Fabian Lohaus; Tobias Hölscher; Hans Neubauer; Mahdi Rivandi; Vera Labitzky; Tobias Lange; André Franken; Bianca Behrens; Nikolas H Stoecklein; Marieta Toma; Ulrich Sommer; Sebastian Zschaeck; Maximilian Rehm; Graeme Eisenhofer; Christian Schwager; Amir Abdollahi; Christer Groeben; Leoni A Kunz-Schughart; Gustavo B Baretton; Michael Baumann; Mechthild Krause; Claudia Peitzsch; Anna Dubrovska
Journal:  Theranostics       Date:  2021-06-26       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.